Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034469 | 0.76 | LMNA (0.32) | TSHRALDH1A1CTSKLMNA | |
| SCHEMBL4420293 | 0.73 | CA12 (0.44) | CA12CA9CA2TSHRMAPK1 | |
| SCHEMBL22616909 | 0.70 | LMNA (0.37) | CA12CA9CA2TSHRCA1 | |
| SCHEMBL971150 | 0.69 | CA12 (0.44) | CA12CA9CA2TSHRMAPK1 | |
| SCHEMBL971151 | 0.69 | CA12 (0.44) | CA12CA9CA2TSHRMAPK1 | |
| SCHEMBL43322 | 0.68 | CA12 (0.48) | CA12CA9CA2TSHRMAPK1 | |
| SCHEMBL18641843 | 0.67 | CA12 (0.43) | CA12CA9CA2TSHRMAPK1 | |
| SCHEMBL968823 | 0.67 | CA12 (0.43) | CA12CA9CA2TSHRMAPK1 | |
| SCHEMBL968822 | 0.67 | CA12 (0.48) | CA12CA9CA2TSHRMAPK1 | |
| SCHEMBL2599770 | 0.67 | CTH (0.37) | ALDH1A1CTSKTP53ALDH2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507761-B2 | Benzopyran derivatives, method of production and use thereof | UNIVERSITE DE LIEGE (BE) | 2009-03-24 | — | — | US | disclosed |
| US-20070112063-A1 | Benzopyran derivatives, method of production and use thereof | UNIVERSITE DE LIEGE (BE) | 2007-05-17 | — | — | US | disclosed |
| EP-1589015-A1 | Benzopyran derivatives, method of production and use thereof | Université de Liège (BE) | 2005-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112063-A1 | Benzopyran derivatives, method of production and use thereof | CBR3, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CA12 2070/4885CA9 1088/4885CA2 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.